Member Info for BrainMyDamage

Rafah been on the cards all day. This is a sudden dump for all airlines. Something odd. We're recovering now, should go blue today.

Must be an error, someone's hit the wrong button. Or something to do with gaza.

I'm soaking it in. A close above 183p would be great. Earnings call Friday should also reflect well on the SP.

Hopefully now the low norm and we can look to 200. There you go, there's the jinx.

It just to hit 180 today, on the cards!

Much ado about not much imo.

Funny if this ended up a blue day.

Maybe it'll be that tennis girl scratching her butt 😂. Another great blue day. Ending the week above 160 would be fantastic.

Has to be an RNS. Someone knows something that's for sure.

Here's to breaking 187 then!

Anyone know next resistance level?

Either FOMO or RNS logged.

Bit of a big wave just hit.

US trades from 2pm will make today even more interesting. An RNS to accompany could blow the doors off.

SP picking up the pace, buys coming in strong.

Flipping nightmare. Is there any scenario we will get money back or are shares now cancelled for good?

The SP should fall till EOD tomorrow in anticipation of new ISA season and FOMO on Thursday. I would then expect decent rises Thursday afternoon and next week.

It's the RNS before the Science day I'm interested in. I don't expect any new update at the Science day. So perhaps RNS week of Feb 20th.

MHRA aren't involved in study design or approval for it, that's the clinical trial outfit sponsored by Avacta. MHRA will assess the study design and outcomes at stage of drug approval. Until then Avacta will focus on being able to present all the necessary data required for some submission of drug approval. Time to get this data is dependant upon phase successes then we enter approval timeline. If there is clear patient benefit but not costing a fortune per dose its easier to get approval. Every drug has reported side effects and these are assessed against patient benefit.

I used to work for the MHRA. Drug safety assessments are long, due to the backlog of requests, and thorough. If though in the case of a drug that has a high positive cost benefit ratio like the covid vaccine, a drug can be prioritised for early safety assessment. There needs to be tangible evidence of high efficacy for prioritisation. Fingers crossed.